Drug: Carteolol Hydrochloride

Carteolol Hydrochloride (carteolol) Ophthalmic Solution USP, 1% is a nonselective beta-adrenoceptor blocking agent for ophthalmic use. The chemical name for carteolol hydrochloride (carteolol) is (±)-5-[3-[(1,1-dimethylethyl) amino]-2-hydroxypropoxy]-3,4-dihydro-2(1H)-quinolinone monohydrochloride. The structural formula is as follows: Each mL of sterile solution contains Active: carteolol hydrochloride (carteolol) 10 mg (1%). Preservative: benzalkonium chloride 0.05 mg (0.005%). Inactives: sodium chloride, monobasic and dibasic sodium phosphate, sodium hydroxide and/or hydrochloric acid (to adjust pH to 6.0 - 8.0) and purified water.

Source: http://www.rxlist.com

The following adverse reactions have been reported in clinical trials with Carteolol Hydrochloride (carteolol) Ophthalmic Solution. Ocular Transient eye irritation, burning, tearing, conjunctival hyperemia and edema occurred in about 1 of 4 patients. Ocular symptoms including blurred and cloudy vision, photophobia, decreased night vision, and ptosis and ocular signs including blepharoconjunctivitis, abnormal corneal staining, and corneal sensitivity occurred occasionally. Systemic As is characteristic of nonselective adrenergic blocking agents, Carteolol may cause bradycardia and decreased blood pressure (See WARNINGS). The following systemic events have occasionally been reported with the use of Carteolol Hydrochloride (carteolol) Ophthalmic Solution: cardiac arrhythmia, heart palpitation, dyspnea, asthenia, headache, dizziness, insomnia, sinusitis, and taste perversion. The following additional adverse reactions have been reported with ophthalmic use of beta1 and beta2 (nonselective) adrenergic receptor blocking agents: Body As a Whole Headache Cardiovascular Arrhythmia, syncope, heart block, cerebral vascular accident, cerebral ischemia, congestive heart failure, palpitation (see WARNINGS). Digestive Nausea Psychiatric Depression Skin Hypersensitivity, including localized and generalized rash Respiratory Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure (see WARNINGS) Endocrine Masked symptoms of hypoglycemia in insulin-dependent diabetics (see WARNINGS) Special Senses Signs and symptoms of keratitis, blepharoptosis, visual disturbances including refractive changes (due to withdrawal of miotic therapy in some cases), diplopia, ptosis. Other reactions associated with the oral use of nonselective adrenergic receptor blocking agents should be considered potential effects with ophthalmic use of these agents. Read the Carteolol Hydrochloride (carteolol) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

The usual dose is one drop of Carteolol Hydrochloride (carteolol) Ophthalmic Solution 1% in the affected eye(s) twice a day. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors, such as acetazolamide, can be instituted.

Source: http://www.rxlist.com

Carteolol Hydrochloride (carteolol) Ophthalmic Solution should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally, because of the potential for additive effects on systemic beta-blockade. Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. Last reviewed on RxList: 10/29/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Carteolol Hydrochloride (carteolol) Ophthalmic Solution 1% has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications.

Source: http://www.rxlist.com

Carteolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see WARNINGS); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see WARNINGS); cardiogenic shock; or hypersensivity to any component of this product. Last reviewed on RxList: 10/29/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

No specific information on emergency treatment of overdosage in humans is available. Should accidental ocular overdosage occur, flush eye(s) with water or normal saline. The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension. In case of ingestion, treatment with Carteolol Hydrochloride (carteolol) Ophthalmic Solution should be discontinued and gastric lavage considered. The patient should be closely observed and vital signs carefully monitored. The prolonged effects of carteolol must be considered when determining the duration of corrective therapy. On the basis of the pharmacologic profile, the following additional measures should be considered as appropriate: Symptomatic Sinus Bradycardia or Heart Block Administer atropine. If there is no response to vagal blockade, administer isoproterenol cautiously. Bronchospasm Administer a beta2-stimulating agent such as isoproterenol and/or a theophylline derivative. Congestive Heart Failure Administer diuretics and digitalis glycosides as necessary. Hypotension Administer vasopressors such as intravenous dopamine, epinephrine or norepinephrine bitartrate.

Source: http://www.rxlist.com

Carteolol Hydrochloride (carteolol) Ophthalmic Solution USP, 1% is supplied as a sterile ophthalmic solution in plastic dispenser bottles of 5 mL (NDC 61314-238-05), 10 mL (NDC 61314-238-10) and 15 mL (NDC 61314-238-15). Store at 15° to 25°C (59° to 77°F) (room temperature) and protect from light. Dist. by: FALCON Pharmaceuticals, Ltd. Fort Worth, Texas 76134, USA. Mfd. by: ALCON LABORATORIES, INC. Fort Worth, Texas 76134, USA. FDA Rev date: 5/22/2001 Last reviewed on RxList: 10/29/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General Carteolol Hydrochloride (carteolol) Ophthalmic Solution should be used with caution in patients with known hypersensitivity to other beta-adrenoceptor blocking agents. Use with caution in patients with known diminished pulmonary function. In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil with a miotic. Carteolol has little or no effect on the pupil. When Carteolol is used to reduce elevated intraocular pressure in angle-closure glaucoma, it should be used with a miotic and not alone. Risk from Anaphylactic Reaction While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated accidental, diagnostic or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. Muscle Weakness Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis and generalized weakness). Carcinogenesis, Mutagenesis, Impairment of Fertility Carteolol hydrochloride (carteolol) did not produce carcinogenic effects at doses up to 40 mg/kg/day in two-year oral rat and mouse studies. Test of mutagenicity, including the Ames Test, recombinant (rec)-assay, in vivocytogenetics and dominant lethal assay demonstrated no evidence for mutagenic potential. Fertility of male and female rats and male and female mice was unaffected by administration of carteolol hydrochloride (carteolol) dosages up to 150 mg/kg/day. Pregnancy Teratogenic Effects Pregnancy Category C Carteolol hydrochloride (carteolol) increased resorptions and decreased fetal weights in rabbits and rats at maternally toxic doses approximately 1052 and 5264 times the maximum recommended human oral dose (10 mg/70 kg/day), respectively. A dose-related increase in wavy ribs was noted in the developing rat fetus when pregnant females received daily doses of approximately 212 times the maximum recommended human oral dose. No such effects were noted in pregnant mice subjected to up to 1052 times the maximum recommended human oral dose. There are no adequate and well-controlled studies in pregnant women. Carteolol Hydrochloride (carteolol) Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether this drug is excreted in human milk, although in animal studies carteolol has been shown to be excreted in breast milk. Caution should be exercised when Carteolol Hydrochloride (carteolol) Ophthalmic Solution is administered to nursing mothers. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Last reviewed on RxList: 10/29/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Women's Health Care an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically Carteolol Hydrochloride. Find what medications you are taking today.